Assistance Publique - Hôpitaux de Paris: Multiple Myeloma trials

The registry lists 18 Multiple Myeloma studies with Assistance Publique - Hôpitaux de Paris as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 2 4Phase 3 2No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Not yet recruitingNCT07348393Phase 2
• Quality of Life Assessment of Caregivers of Patients With Multiple MyelomaNot yet recruitingNCT07276230Not applicable
• Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without DexamethasoneRecruitingNCT06561854Phase 3
• Early Assessment of Cardiac Function After Treatment With CAR-T CellsRecruitingNCT06350994
• Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology PatientsRecruitingNCT06133426Not applicable
• Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.RecruitingNCT05203003
• Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory HemopathiesNot yet recruitingNCT04702932
• Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple MyelomaRecruitingNCT03490084
• A Real-World Study of Bispecific Antibodies in Multiple MyelomaCompletedNCT06359067
• Isatuximab in Type I CryoglobulinemiaStatus unknownNCT05114109Phase 2
• Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)Status unknownNCT04609150
• Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine CareTerminatedNCT04111809
• Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 TrialWithdrawnNCT04024384Phase 2
• Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaActive, not recruitingNCT03836014Phase 3
• Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous GraftWithdrawnNCT03393273Phase 2
• Autologous Stem Cell Transplantation for Myeloma Patients Over 65 YearsStatus unknownNCT01671826
• "WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free SurvivalCompletedNCT01171430Not applicable
• Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.TerminatedNCT00748631Not applicable